Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Abstract Background Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durvalumab after CCRT is whether the incidence of symptomatic radiation pneum...

Full description

Bibliographic Details
Main Authors: Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Radiation Oncology
Subjects:
Locally advanced non-small cell lung cancer
Concurrent chemoradiotherapy
Radiation pneumonitis
Dosimetric factor
Durvalumab
Online Access:https://doi.org/10.1186/s13014-021-01979-z

Internet

https://doi.org/10.1186/s13014-021-01979-z

Similar Items